Expression of the thymosin beta 4 gene during differentiation of hematopoietic cells.

Shimamura R, Kudo J, Kondo H, Dohmen K, Gondo H, Okamura S, Ishibashi H, Niho Y

Blood1 Sept 1990Cited by 28 (Europe PMC)

PMID2393720DOI10.1182/blood.v76.5.977.977PepBankPUB-02393720

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

No result from this study comes from a test of the peptide.

Natural levels measured7

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

01HumanEndogenous levelObservational studyMechanism
In leukemic cells from patients, the thymosin beta‑4 gene was highly expressed in a lymphoid lineage, especially adult T-cell leukemia cells, rather than in a granulocyte lineage.
In plain wordsIn leukemia cells from patients, the body's own thymosin beta‑4 gene was more active in lymphoid than in granulocyte cells.
Peptide
Thymosin beta-4 (human)
Outcome
IncreaseTβ4 gene expression in lymphoid versus granulocyte leukemia cells
Study
n: not reported in source
Comparator
Granulocyte lineage leukemic cells
Outcome group
Gene expression · Cancer
Source sentences
Summary
Among leukemic cell samples obtained from leukemia patients, the T beta 4 gene was highly expressed in a lymphoid lineage, especially in adult T-cell leukemia (ATL) cells, rather than in a granulocyte lineage.
1 context sentence(design, population, supporting numbers)
Summary · context
To investigate the mechanism of T beta 4 expression, we studied T beta 4 gene expression in various leukemic cells and in established cell lines.
This result measures the body's own Thymosin beta-4 (human). Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-0239372001
02HumanEndogenous levelObservational studyMechanism
The thymosin beta‑4 gene was more transcriptionally active in chronic than in acute B-cell leukemia and was inactive in plasma cell leukemia.
In plain wordsIn leukemia cells, the body's own thymosin beta‑4 gene was more active in chronic than in acute B-cell leukemia and inactive in plasma cell leukemia.
Peptide
Thymosin beta-4 (human)
Outcome
MixedTβ4 gene transcription in chronic, acute B-cell and plasma cell leukemia
Study
n: not reported in source
Outcome group
Gene expression · Cancer
Source sentences
Summary
The T beta 4 gene was more transcriptionally active in chronic B-cell leukemia than in acute B-cell leukemia, while it was inactive in plasma cell leukemia.
1 context sentence(design, population, supporting numbers)
Summary · context
To investigate the mechanism of T beta 4 expression, we studied T beta 4 gene expression in various leukemic cells and in established cell lines.
This result measures the body's own Thymosin beta-4 (human). Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-0239372002
03HumanEndogenous levelObservational studyMechanism
Cells from one of the adult T-cell leukemia patients transcribed a heterogeneous thymosin beta‑4 message.
In plain wordsIn cells from one adult T-cell leukemia case, the body's own thymosin beta‑4 gene gave a mixed message.
Peptide
Thymosin beta-4 (human)
Outcome
Not applicableHeterogeneous Tβ4 message in an ATL patient
Study
n: not reported in source
Outcome group
Gene expression · Cancer
Source sentences
Summary
We also found that cells from one of the ATL patients transcribed a heterogeneous message.
1 context sentence(design, population, supporting numbers)
Summary · context
To investigate the mechanism of T beta 4 expression, we studied T beta 4 gene expression in various leukemic cells and in established cell lines.
This result measures the body's own Thymosin beta-4 (human). Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-0239372003
04HumanEndogenous levelObservational studyOther
Only 1 of 20 genomes from normal or hematopoietic malignant cells showed restriction fragment length polymorphism of the thymosin beta‑4 gene.
In plain wordsIn DNA from normal and blood cancer cells, only 1 of 20 genomes showed a variant pattern of the body's own thymosin beta‑4 gene.
Peptide
Thymosin beta-4 (human)
Outcome
Not applicableRestriction fragment length polymorphism of the Tβ4 gene
Study
n: not reported in source
Outcome group
Gene expression · Cancer
Measurements
genomes with polymorphism
1 of 20 genomes
normal or hematopoietic malignant cells
Source sentences
Summary
Only 1 of 20 genomes from normal or hematopoietic malignant cells showed restriction fragment length polymorphism.
1 context sentence(design, population, supporting numbers)
Summary · context
To investigate the mechanism of T beta 4 expression, we studied T beta 4 gene expression in various leukemic cells and in established cell lines.
This result measures the body's own Thymosin beta-4 (human). Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-0239372007
05LabEndogenous levelIn vitro (cells)Mechanism
Thymosin beta‑4 mRNA increased in MOLT-3 cells during differentiation induced by 12-O-tetradecanoylphorbol-13-acetate (TPA).
In plain wordsIn MOLT-3 cells, the body's own thymosin beta‑4 mRNA rose when the cells were pushed to differentiate with TPA.
Peptide
Thymosin beta-4 (human)
Outcome
IncreaseTβ4 mRNA in MOLT-3 cells after TPA
Study
n: not reported in source
MOLT-3 cells
Outcome group
Gene expression · Cancer
Source sentences
Summary
T beta 4 messenger RNA increased in MOLT-3 during differentiation by 12-O-tetradecanoylphorbol-13-acetate (TPA)
1 context sentence(design, population, supporting numbers)
Summary · context
To investigate the mechanism of T beta 4 expression, we studied T beta 4 gene expression in various leukemic cells and in established cell lines.
This result measures the body's own Thymosin beta-4 (human). Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-0239372004
06LabEndogenous levelIn vitro (cells)Mechanism
Thymosin beta‑4 mRNA increased in HL60 cells induced by TPA or dimethylsulfoxide.
In plain wordsIn HL60 cells, the body's own thymosin beta‑4 mRNA rose after TPA or dimethylsulfoxide.
Peptide
Thymosin beta-4 (human)
Outcome
IncreaseTβ4 mRNA in HL60 cells after TPA or dimethylsulfoxide
Study
n: not reported in source
HL60 cells
Outcome group
Gene expression · Cancer
Source sentences
Summary
T beta 4 messenger RNA increased in MOLT-3 during differentiation by 12-O-tetradecanoylphorbol-13-acetate (TPA), in HL60 cells induced by TPA or dimethylsulfoxide
1 context sentence(design, population, supporting numbers)
Summary · context
To investigate the mechanism of T beta 4 expression, we studied T beta 4 gene expression in various leukemic cells and in established cell lines.
This result measures the body's own Thymosin beta-4 (human). Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-0239372005
07LabEndogenous levelIn vitro (cells)Mechanism
Thymosin beta‑4 mRNA increased in K562 cells stimulated by cytosine arabinoside or hemin.
In plain wordsIn K562 cells, the body's own thymosin beta‑4 mRNA rose after cytosine arabinoside or hemin.
Peptide
Thymosin beta-4 (human)
Outcome
IncreaseTβ4 mRNA in K562 cells after cytosine arabinoside or hemin
Study
n: not reported in source
K562 cells
Outcome group
Gene expression · Cancer
Source sentences
Summary
K562 cells stimulated by cytosine arabinoside or hemin.
1 context sentence(design, population, supporting numbers)
Summary · context
To investigate the mechanism of T beta 4 expression, we studied T beta 4 gene expression in various leukemic cells and in established cell lines.
This result measures the body's own Thymosin beta-4 (human). Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-0239372006

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
13 Oct 2026, 01:52 UTC
Study results updated
Version 1
12 Oct 2026, 18:17 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.